Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms Indium In 111 Panitumumab |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), SPECT(Single-photon emission-computed tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 1 | US | 22 Aug 2023 |
Phase 1/2 | 45 | radiochemotherapy+Panitumumab | dadcyotbkr(alcpsvfxay) = wxhopwmumm igiqesfqnw (lqarzlwiig, ccbhcfmftq - nxbnfalqfs) View more | - | 01 Jul 2024 | ||
Phase 2/3 | RAS Wild Type Colorectal Cancer RAS wild-type | 648 | Panitumumab+FOLFOX4 | femkgdgycd(ymypbulubz) = eirdoqdwyf iblmccivnp (bwgxlbfmfb ) View more | Positive | 08 Jul 2020 | |
FOLFOX4 | femkgdgycd(ymypbulubz) = wvhzjnxxog iblmccivnp (bwgxlbfmfb ) View more |